ORIC PHARMACEUTICALS INC (ORIC)
Health Care · Oncology / targeted cancer therapeutics · NASDAQ
ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
What ORIC PHARMACEUTICALS INC does
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. The company is advancing two lead product candidates: rinzimetostat (formerly ORIC-944) and enozertinib (formerly ORIC-114), both in clinical development. ORIC focuses on identifying and developing therapeutics that address unmet medical needs in oncology through precision medicine approaches.
Themes: oncology drug development, targeted cancer therapy, precision medicine
Fundamentals
- Price$14.20 as of 2026-08-21 close
- Market cap$1.5B as of 2026-08-21
- 1-year return+46.5% 2025-08-21 close $9.69 → 2026-08-21 close $14.20
- P/En/a earnings data not available
- ROE-35.4% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.96 as of 2026-08-24
- Last reported earnings2026-08-03 SEC EDGAR Form 8-K (Item 2.02)
How ORIC compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ORIC PHARMACEUTICALS INC looks technically
ORIC PHARMACEUTICALS INC (ORIC) is trading 32.3% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 5 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 4.9% below its 52-week high (its highest price of the past year).
Trend
9
| Distance from the 200-day | it is trading 32.3% above its 200-day average, the long-term trend line — a longer-term uptrend | +32.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $11.26 | $11.26 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $10.74 | $10.74 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 12.57. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 5 trading days ago — a "golden cross", a bullish long-term signal | 5 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 32.3% above | +32.3% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 44, with buyers in control | 43.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.3 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($10.64 to $14.68) — its "stochastic" reading is 88 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 88.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 14 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.93 | $14.93 |
|---|---|---|
| From the 52-week high | it is 4.9% below its 52-week high (its highest price of the past year) | -4.9% |
| Above the 52-week low | it is 96.4% above its 52-week low (its lowest price of the past year) | +96.4% |
| Below the 52-week high | it is 4.9% below its highest point of the past year | 4.9% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $37.00 (set on 2021-03-03) | $37.00 |
| Given back of the 52-week move | over the past year its closes ranged ($7.47 to $14.65), and it has given back only a small part of its rise from last year’s low — 6% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $9.99 to $10.22. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 6.3% |
| From the all-time high | it is 61.6% below its all-time high | -61.6% |
| Nearest price level | it is sitting right on a support level at $14.14 — a price it turned at three times since 2026-02-25, most recently on 2026-08-11. Since 2024-08-21 it has 15 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.4% |
| All-time low | its lowest closing price on record is $2.36 (set on 2022-11-04) | $2.36 |
| Above the all-time low | it is 501.7% above its all-time low | +501.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 57th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.7868 between its high and its low — about 5.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.7868 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $10.74 and $15.27 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $10.74 – $13.00 – $15.27 |
| Typical daily range (% of price) | its price moves about 5.5% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.5% |
| Stretch from the 200-day average | it is trading 4.4 daily ranges above its 200-day average price (32.3% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.4 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.63× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.6% since the prior reading | -1.6% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.02 toward sell |
Candlestick patterns
3
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a bullish engulfing | 3 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 3 sessions ago |
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Open gap | it gapped 2.3% below the previous close 1 session ago and has not traded back through the level it left behind at 14.65 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -2.3% |
| Gap filled | a 2.0% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 28.8 percentage points (the stock gained 31.1% while the market gained 2.3%) | +28.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 64.8 percentage points (the stock gained 67.8% while the market gained 3.1%) | +64.8% |
| vs market, 6 months | over the past 6 months this stock beat the market by 16.7 percentage points (the stock gained 27.8% while the market gained 11.1%) | +16.8% |
| vs market, 12 months | over the past 12 months this stock beat the market by 26.1 percentage points (the stock gained 46.5% while the market gained 20.5%) | +26.1% |
Signal agreement
2
| Bullish technical signals | 7 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 7 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 36% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.3% of the share price. | +36.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 35% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $10.52 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +35.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% above the average price paid since it last reported on 2026-08-03 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $13.29 — a volume-weighted average of daily closes over 15 sessions, not a true tick-by-tick VWAP. | +6.8% |
Price levels it has turned at before
ORIC last closed at $14.20 on 2026-08-21. Since 2024-08-21 it has turned at 15 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $14.14 | Support | 0.4% below the last close | turned there three times · 2026-02-25 to 2026-08-11 |
| $12.59 | Support | 11.3% below the last close | turned there three times · 2025-12-08 to 2026-07-27 |
| $12.03 | Support | 15.3% below the last close | turned there twice · 2025-07-23 to 2026-07-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $12.57.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $12.57 and $13.25 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 1 trading day, since 2026-08-21.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Broke out to a new 20-day high · in a strong, established uptrend (ADX) · Analyst price target recently CUT | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.29 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$20.67 range $14.00 – $27.00; median $21.50
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ORIC
- Consensus EPS estimate-$0.374 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["High reliance on the success of clinical trials for product candidates.","Significant need for additional capital to fund research, development, and eventual commercialization.","Risks associated with protecting intellectual property and potential infringement of third-party rights."]
What changed in the latest 10-Q
AI-assisted comparison of ORIC's 10-Q filed 2026-05-04 against the prior one filed 2025-11-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to audited financial statements and Form 10-K for year ended December 31, 2025, filed February 23, 2026 (newer filing)
- Rinzimetostat announced as the proprietary name for the PRC2 inhibitor (formerly ORIC-944)
- March 2026 Phase 1b dose optimization data reported with 5-month median follow-up and 84% landmark rPFS
- Selection of 400 mg QD rinzimetostat in combination with darolutamide as recommended Phase 3 dose (RP3D)
- Description of rinzimetostat demonstrating 'highly differentiated, potential best-in-disease safety profile'
- Reference to planned Phase 3 registrational trial named 'Himalayas-1' for rinzimetostat in post-abiraterone mCRPC
- December 2025 Phase 1b data reported at ESMO Asia Congress with treatment-naïve and previously treated NSCLC patients
- Selection of 80 mg QD oral enozertinib as monotherapy dose for potential Phase 3 development
- Clinical trial and supply agreement with Johnson & Johnson to evaluate enozertinib in combination with 'amivantamab and hyaluronidase-lpuj subcutaneous injection (SC amivantamab)'
- Phase 1b trial initiated in first quarter of 2025 for enozertinib with amivantamab
- Removed:
- Reference to audited financial statements and Form 10-K for year ended December 31, 2024, filed February 18, 2025
- ORIC-944 as the product candidate name (replaced with 'Rinzimetostat')
- Specific July 2024 announcement reference for initiation of combination dosing
- Reference to 'first half of 2025' reporting of Phase 1b combination data from 17 patients
- Specific PSA response metrics (55% PSA50, 40% confirmed, 20% PSA90, 59% with ctDNA clearance, 76% with >50% ctDNA reduction)
- Cutoff date specification 'September 22, 2025' for November 2025 data
- Statement 'expect to report dose optimization data in the first quarter of 2026'
- Statement 'expect to initiate...Phase 3 registrational trial...in the first half of 2026'
- Enozertinib description including 'HER2 exon 20 mutations' as targeted mutations
- References to 'formerly ORIC-114' designation for enozertinib
- Statement 'We are enrolling a Phase 1b trial' (changed to past tense in newer filing)
- Phrase 'selectively targets EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations'
- Reference to 'advanced solid tumors' as enrollment description
- Expected 'fourth quarter of 2025' comprehensive data update reference
- References to expected data including '2L+ EGFR atypical cohort', '2L EGFR exon 20', and '2L+ HER2 exon 20' cohorts
- Reference to 'subcutaneous (SC) amivantamab' alone (without hyaluronidase-lpuj specification)
- Expected 'mid-2026' data timing for amivantamab combination and first-line EGFR atypical monotherapy
- Statement about initiating Phase 3 trial(s) 'in 2026, in EGFR exon 20, EGFR atypical, and/or HER2 exon 20 mutations'
- Paragraph regarding August 12, 2025 strategic pipeline prioritization and elimination of discovery research group
- Reworded:
- Changed from 'Janssen Research & Development, LLC, a Johnson and Johnson company (Johnson & Johnson)' to 'Johnson & Johnson' for first mention
- Changed from 'Bayer Consumer Care AG (Bayer)' to 'Bayer' for first mention
- Changed from 'androgen receptor (AR) inhibitor' to 'AR inhibitor' (abbreviation already defined)
- Newer filing emphasizes 'provisional recommended Phase 2 doses (RP2Ds)' vs older 'recommended Phase 2 dose (RP2D) levels'
- Changed from 'only one patient experienced a Grade 3 TRAE' to same language but in different data context (November vs March cutoff)
- Changed enozertinib target description from 'EGFR exon 20, EGFR atypical, and HER2 exon 20 mutations' to 'EGFR exon 20 insertion and EGFR atypical mutations' and later 'EGFR exon 20 insertion and EGFR PACC patients'
- Added specification '80 mg QD oral enozertinib' vs previously '80 mg and 120 mg daily QD' options
- Notes:
- The newer filing appears to be a partial excerpt and cuts off mid-sentence regarding enozertinib dosing/follow-up continuation, limiting full comparison of later sections
- The older filing includes a concluding paragraph about August 2025 strategic pipeline prioritization that is not present in the newer excerpt provided, but this may be due to truncation rather than removal
Risk Factors
- Added:
- In newer filing (2026-05-04), forward-looking statements include language about strategic pipeline prioritization and reduction in workforce impacts (already present in older filing as well, but confirmed in newer)
- Removed:
- Removed from newer filing (2026-05-04): bullet point regarding expectations about periods qualifying as emerging growth company, smaller reporting company, or non-accelerated filer under JOBS Act
- Reworded:
- Product candidate name changed from 'ORIC-944' in older filing (2025-11-13) to 'rinzimetostat' in newer filing (2026-05-04), appearing multiple times in forward-looking statements section
- Product candidate reference changed from 'enozertinib (formerly ORIC-114)' in older filing to 'enozertinib' in newer filing (shortened form, no longer includes former name)
- Notes:
- The provided text includes table of contents and financial statements sections; comparison focused on forward-looking statements special note section which is most substantive
- Page number changes (Risk Factors moved from page 21 to page 20) are formatting changes only
- Balance sheet dates differ between filings (March 31, 2026 vs September 30, 2025) reflecting different reporting periods
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 3 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 3 sells ($161062) — 1 selling insider
- Last 180 days0 buys · 3 sells ($161062) — 1 selling insider
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-24. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ORIC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ORIC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 20,378,102
- Reported value $258,190,551
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 1 increased, 4 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ORIC had 21,804,868 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ORIC had 21.0% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.55 days to cover at the same settlement.
- Reported short interest (shares) 21,804,868
- Short interest (% of shares outstanding) 21.0%
- Prior settlement (shares) 22,053,046
- Reported change -1.13%
- Days to cover (reported) 13.55
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Genentech / Roche
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
ORIC PHARMACEUTICALS INC is found in…
ORIC ranks in…
Frequently asked questions
What does ORIC PHARMACEUTICALS INC (ORIC) do?
ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for difficult-to-treat cancers. The company is advancing two lead product candidates: rinzimetostat (formerly ORIC-944) and enozertinib (formerly ORIC-114), both in clinical development. ORIC focuses on identifying and developing therapeutics that address unmet medical needs in oncology through precision medicine approaches.
What sector is ORIC PHARMACEUTICALS INC (ORIC) in?
ORIC PHARMACEUTICALS INC (ORIC) is classified in the Health Care sector. Its industry is Oncology / targeted cancer therapeutics. It trades on NASDAQ.
Who are ORIC PHARMACEUTICALS INC's (ORIC) competitors?
Notable peers of ORIC PHARMACEUTICALS INC (ORIC) include Genentech / Roche. This peer set is informational only — not financial advice.
Is ORIC PHARMACEUTICALS INC (ORIC) overbought or oversold right now?
ORIC PHARMACEUTICALS INC (ORIC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ORIC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.